SYDNEY, Australia, March 21, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 10,232,038) entitled “Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response” by the United States Patent Office.
This United States patent was filed as a continuation application, and follows the grant of the United States parent patent which was issued in February 2017, as announced to the market.
This new patent provides intellectual property protection for Immutep’s method of treating cancer by the administration of a chemotherapy agent, and a plurality of doses of eftilagimod alpha (“efti” or “IMP321”) which is used to generate a monocyte mediated immune response. Importantly, the granted patent claims support the application of efti in Immutep’s ongoing AIPAC clinical trial in metastatic breast cancer. The patent will expire on 3 October 2028.
Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
Further information can be found on the Company’s website www.immutep.com or by contacting:
Jay Campbell, Chief Business Officer, Immutep Limited
+1 (917) 860-9404; firstname.lastname@example.org
Garth Russell, LifeSci Advisors
+1 (646) 876-3613; email@example.com
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; firstname.lastname@example.org